Industry: Health Care – Biotechnology: Pharmaceutical Preparations
Stock Symbol: ACTU – NASDAQ
Animal Usage: Animal Testing
Actuate Therapeutics is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.
Supporting Evidence:
The company stated in the following report that they exploit animals for product testing.
“The starting dose and cycle duration were chosen based on animal toxicology studies evaluating elraglusib administered intravenously three times per week for 4 weeks at doses of up to 50 mg/kg in rats and 20 mg/kg in dogs.” (Page 2) Read the full document
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company’s lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
Company Website: https://actuatetherapeutics.com